La gnomique dans lEspace Europen de la Recherche

Le 6me programme cadreLe contexte politique

Sixth Framework Programme 2002-2006

(Global budget European Community 16.270 M )

FP5/QoL : mio 2.2FP6/TP1+TP5 : mio 3.01800 Projects~ 400 TI~ 200 NI80%20%LESS with MORE : less projects, higher focussing but more organisation implied

5th Framework Programme(1998 - 2002)

The 6th Framework Programme(2002 - 2006)

Quality of Life programmeThematic Priority 1 or 5Public dialogueInnovationandtechnologytransfer initiativeswet scienceBioethicsResearchSocio-economicresearch

EthicsPublicdialogueInnovationand competitivenesswet scienceAcademia - Industry - EngineeringRegulation and governanceFragmentation

Life Sciences, Genomics and Biotechnology for Health (FP6) Advanced Genomics and its applications for health (1100 M)

Fundamental knowledge and basic tools for functional genomics in all organisms (Structural genomics; proteomics; comparative genomics; bioinformatics; Multidisciplinary genomics approaches to basic biological processes)

Application of knowledge and technologies in the field of genomics and biotechnology for health (Technology platforms; support to start-up companies)Combating major diseases (1155 M)

Application-oriented approach to medical genomics knowledge (Cardiovascular disease, diabetes and rare diseases ; resistance to antibiotics ; Studying the brain and combating diseases of the nervous system ; Studying human development and the ageing process) Broader biomedical approach (cancer, poverty-related infectious diseases)

Research

European Commission

BIONOVA 03, Padua 04-06 May 2003 *

Structural Proteomics in Europe

Executive Committee

Training

Networking

Research

EC contribution: 13.7 M17 partners

develop technologies for high throughput 3D structure determination of +500 medically relevant proteins

Still FP 5 !

Fundamental knowledge and basic tools for functional genomics in all organisms

Gene expression and proteomics

Structural genomics

Comparative genomics and population genetics

Bioinformatics

Multidisciplinary functional genomics approaches to basic biological processes

Fundamental knowledge and basic tools for functional genomics in all organisms

Structural genomics

FIRST CALL TOPICS

PROJECTS FUNDED

Structure determination of membrane proteins3D electron microscopy

Innovative technologiesfor synchrotrons

E-MeP (IP) Integrated membrane protein action + Membrane protein structural genomics network3D-EM (NOE)New EM approaches for studying protein complexes and cellular supramolecular architectureBIOXHIT (IP) Biocrystallography on a highly integrated technology platform for European structural genomics

Fundamental knowledge and basic tools for functional genomics in all organisms Structural genomicsLSH-2003-1.1.2-1: Comparative structural biology of viral replication IP. The focus should be on developing new approaches, tools and technologies for collecting comprehensive structural information on the replicative machinery of RNA viruses to facilitate the identification of potential new drug targets.

LSH-2003-1.1.2-2: Structure determination of large protein complexes IP. The focus should be on the high throughput isolation of cellular protein complexes under physiological conditions and their structural analysis.

SECOND CALL TOPICS

Fundamental knowledge and basic tools for functional genomics in all organismsMultidisciplinary functional genomics approaches to basic biological processesMITOCHECK (IP) Regulation of mitosis by phosphorylation FUNGENES (IP) Functional genomics in engineered mouse ES cellsNo project selected

LYMPH/ANGIOGENOMICS (IP) Genome wide discovery and functional analysis of novel genes in lymph/angiogenesisFIRST CALL TOPICS PROJECTS FUNDEDThe cell cycle

Non-human embryonic stem cellsErythroid development and disordersLymph/angiogenesis

Epigenetics

Chronic inflammation

Ubiquitin-proteasome pathway

Fundamental knowledge and basic tools for functional genomics in all organismsMultidisciplinary functional genomics approaches to basic biological processesFIRST CALL TOPICS PROJECTS FUNDEDTHE EPIGENOME (NoE) Epigenetic plasticity of the genome + The European epigenetics networkMAIN (NoE) Targeting cell migration in chronic inflammationNo project selected

Fundamental knowledge and basic tools for functional genomics in all organismsMultidisciplinary functional genomics approaches to basic biological processesSECOND CALL TOPICS LSH-2003-1.1.5-1: Functional genomics approaches in animal models to study human kidney disease IP/NOE. The focus should be on integrating different expertise, animal models and functional genomics platforms to discover the genetic mechanisms that underlie kidney development and cause kidney disease.

LSH-2003-1.1.5-2: Functional genomics approaches to the study of peroxisomes in health and disease IP/NOE. The focus should be on using functional genomics approaches and cell and animal models to decipher the entire spectrum of biological functions performed by peroxisomes and to evaluate their roles in disease.

LSH-2003-1.1.5-5: DNA damage and repair mechanisms in health and disease IP. The focus should be on using multidisciplinary functional genomics approaches to decipher the core molecular mechanisms of DNA damage and repair. LSH-2003-1.1.5-6: Functional genomics approaches in animal models to study human immunological disease IP/NOE. The focus should be on bringing together different expertise from academic and industrial (including SMEs) laboratories to generate a joint programme of activities that combines research on model organisms and functional genomics to investigate the immune system for elucidating the genetic basis of immunological disease, thereby facilitating the development of new diagnostics and therapeutic tools.

Fundamental knowledge and basic tools for functional genomics in all organismsMultidisciplinary functional genomics approaches to basic biological processesSECOND CALL TOPICS

Fundamental knowledge and basic tools for functional genomics in all organisms

Multidisciplinary functional genomics for basic mechanisms of:Transcription activation, signal transduction, intracellular communication, non coding genomic information, integration of genes, in silico predicion and simulation of regulatory networksSTREPs and CAs16 STREPs fundedLow abundance mRNAs and proteins, role of small RNAs, nanomachines, apoptosis, comparative genomics in protozoa, standardisation, in silico modelling of macromolecules.CA: Structuring mouse genomics and other models, systems biology, model organisms resources, biobanksFIRST CALL TOPICS SECOND CALL TOPICS

Application of knowledge and technologies in the field of genomics and biotechnology for health Rational and accelerated development of new, safer and more effectivedrugs including pharmacogenomics approaches

Development of new diagnostics

Development of new in-vitro tests to replace animal experimentation

Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, forexample those on neurological and neuromuscular disorders) andimmunotherapies

Innovative research in post-genomics, which has high potentialfor application

Application of knowledge and technologies in the field of genomics and biotechnology for health New drugs (6)

Protein-kinases - novel drug targets (IP) Drugs for depression (IP)Replication & integration of HIV (IP)Individualised medicines (missing)Blood substitutesG-protein coupled receptorsEuropean Labcourse: gene vectors (SSA) Diagnostics (2)

Non-invasive advances in prenatal diagnosis (NoE) Molecular diagnostics of kidney diseaseDiagnostic for prion diseases (missing) In Vitro alternatives (3)

Hazard and risk assessment ofreproductive toxicity (IP)In vitro assays for long term toxicityAlternative methods (SSA)

New Therapies (9)

European consortium for stem cell research (IP)Allogeneic stem cell transplantation (IP)Mesenchymal stem cells for connective tissue disorders (IP)Genome & protein information for immune recognitionStem cells for myocardial repairDendritic - cells / - Vaccines / - CancerEuropean Labcourse: therapy (SSA)

Post Genomics (6)

New approaches for autoimmune diseases (IP)Pharmaceuticals from plants (IP)Antibiotic resistance - Gyrase inhibitors / - GlycopeptidesGenomics - BiocatalysisPost-genomics drug discovery

Application of knowledge and technologies in the field of genomics and biotechnology for health Post GenomicsExploitation of fungal genomics and filamentous fungal biotechnology for human health CARNA as a human therapeutic tool IPPost-genomics approach to the studyof human pathogens NoEInduction of transplanttolerance IPNovel biosafe propagationdeficient virus vectorsaimed at prevention and treatment of infectious diseases STREPNew bioassays and biosensors for detection of harmful microbes STREP FIRST CALL:

New approaches for autoimmune diseases (IP)Pharmaceuticals from plants (IP)Antibiotic resistance - Gyrase inhibitors / - GlycopeptidesGenomics - BiocatalysisPost-genomics drug discoverySECOND CALLFungall cell-wall as a targetof antifungal therapies STREPUse of RNAi as tool of post-genomic analysis SSA

Priority 5 Food Quality and Safety

Epidemiology of food related diseases and allergies Impact of food on health Traceability processes Methods of analysis/detection and control of chemical contaminants and pathogenic microorganisms Safer production methods and healthier foodstuffs Impact of Animal feed on Human Health Environmental health risks

strategic objectives

- nutrition science benefiting from new genomic technologies

- virtual centre of excellence

- transferring acquired knowledge to stakeholders groups

process of activities

integrating activities

joint research activities

activities to spread excellence

Grain Legumes Integrated ProjectGrain legumes studied: pea, bean, faba bean, chickpea, lentil and lupin (the legume Medicago truncatula is used as a model system)Proposed budget:Total Costs: 28.153.743Requested EC Contribution 16.961.701(50% budget requested by 10 partners)New strategies to improve grain legumes for food and feed : to increase competitiveness of grain legumes in Europe to improve Europes self-sufficiency in plant proteins66 partners from 19 countries (~80 labs; 9 SMEs): UK; BE; BG; CH; CZ; DE; DK; ES; FR; HU; IL; IT; NL; NO; PL; PT; SE; AU; US

Grain Legumes Integrated Project

Cooperation and coordination of national or regional research and innovation activities (i.e. programmes)ERA-NET

Participants: ERA-PG builds on national research programmes in plant genomics (NL, AT, BE, DK, FI FR, DE, IT, NO, SP, UK). Other states may join (BG, EE, GR, HU, IE, PO, PT, RO, SW)

Objectives:Improved co-ordination of national plant genomics research programmes

Optimising investments for plant genomics research and supporting policies

Creating long term perspectives and improved validation of RTD strategies

Means: information exchange, web portal, short-term exchange of pgm managers, benchmarking, joint database of experts, position papersERA-NET co-ordination action in plant genomics (ERA-PG)

La gnomique dans lEspace Europen de la Recherche

Le 6me programme cadreLe contexte politique

A European Strategy for Life Sciences and Biotechnology: The Action Plan - COM (2002) 271. Harvesting the Potential

The resource Baseinvesting in peoplegenerating and exploiting knowledgeintellectual property protectioncapital baseNetworking Europes Biotechnology CommunitiesA pro-active role for public authorities

3. Responding to global challengeA European agenda for international collaborationEuropes responsibilities towards the developing world

2. Governing Life Sciences and Biotechnology

Societal scrutiny and dialogueDeveloping Life Sciences and Biotechnology in harmony with ethical values and social goalsDemand-driven applications through informed choiceConfidence in science-based regulatory oversight

4. Implementation and coherence across policies, sectors and actors

TECHNOLOGY PLATFORMSEuropean Council in March 2003 ...European Research and Innovation Area to be strengthened to the benefit of all in the enlarged EU by creating European technology platforms bringing together technological know-how, industry, regulators and financial institutions to develop a strategic agenda for leading technologies, in areas such as plant genomics

Technology Platforms have been identified as important elements for increasing competitiveness in the Communication Industrial policy in an enlarged Europe (Dec. 2002) and the 3% action plan (April 2003)

3% Action Plan:better use of public financing to increase leverage effect on private investment;R&D in corporate strategies and management.Progress jointly (open process of co-ordination; European technology platforms)Improve public support to research and innovation (human resources; academia-industry links; mix of public financing instruments; ..); Redirect public spending towards research and innovation (refocus public spending; state aid rules; public procurement; ...)

Research

European Commission

Strategic Technology Platforms

Objective of a Technology Platformto bring together all stakeholders (research, industry, regulators, policy makers) to develop a long term vision for the deployment and growth of new technologies, including the downstream regulatory environment in which technologies are developed and marketedto create a coherent strategy and action plan to deliver agreed programs of activities and optimise the benefits for all to elaborate on and follow-up a strategic research agenda

Strategic EU technology platforms are being established in the areas of plant genomics & biotechnology and new safe medicines faster

Research

European Commission

Technology Platform on Plant Biotechnology and Plant Genomics Agro-bio-tech (GMO and non-GMO) food and beverage farming paper industry bio-fuels, etc.

The current political climate on GMO-crops and GMO-food risks have a negative impact on competitiveness of EU research and industry also in other important areas of plant genomics and biotech.

A first brainstorming meeting with stakeholders took place in Brussels on July 15th 2003.

Plant GenomicsSHARED PLATFORMEPSOIndustryFarmers cooperativesBiotech entrepreneursConsumer groupsEnvironmental NGOPolicy-makersPolicy DGs

Improving the diagnostic and therapeutic arsenal for health careLIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH

TOWARDS JOINT INDUSTRIAL PROJECTS Treaty on the European Union Article 171 The Community may set up joint undertakings or any other structure necessary for the efficient execution of Community research, technological development and demonstration programmesE.g. GALILEO Joint UndertakingMembers are EC, ESA, EIB, private enterprises. A tendering process is foreseen. Encompasses R&D, validation of developments, demonstration, coordination with national activities. Mio 5.0 to be subscribed by entrerprises, down to 250 000 for SMEs

European Research CouncilJoint Industrial Projects

Clinical applications of post-genomic information:- functional analysis of human genome and its application to diagnosis and therapy of diseases, including mitochondrial disorders- quality and safety control of new tools (gene vectors, stem cells) for clinical use- optimisation, standardisation and quality assessment and assurance of post-genomic technology- adverse reactions to drugs, in particular those of immunological origin

Post-genomic approaches:- for the development of new tools for the rapid diagnosis of pathogenic infection and new targets for anti-microbial agents- for allergy and autoimmune diseases- for complex multifactorial diseases